Endpoints News 24. Feb. 2026 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Endpoints News 24. Feb. 2026 Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push
Endpoints News 23. Feb. 2026 FDA unveils long-awaited guidance on new pathway for individualized therapies
Endpoints News 23. Feb. 2026 AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago
Endpoints News 23. Feb. 2026 A federal experiment opens up a new market for digital health — if it works